Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Bendamustine
Drug: Bortezomib

First Posted Date: 2007-01-25

Last Posted Date: 2015-04-03

Lead Sponsor: Peter Moosmann

Target Recruit Count: 12

Registration Number: NCT00426855

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: bortezomib
Drug: docetaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2007-01-23

Last Posted Date: 2011-11-16

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT00425750

Locations: 🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
🇺🇸
MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, United States
🇺🇸
Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States

and more 4 locations

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2007-01-17

Last Posted Date: 2020-10-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT00422799

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib

First Posted Date: 2007-01-04

Last Posted Date: 2010-06-22

Lead Sponsor: Nordic Myeloma Study Group

Target Recruit Count: 400

Registration Number: NCT00417911

Locations: 🇩🇰
Hæmatologisk afdeling L Amtssygehuset i Herlev, Herlev, Denmark
🇸🇪
Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus, Umeå, Sweden
🇸🇪
University Hospital Lund, Lund, Sweden

and more 17 locations